Chip-Man Technologies this week said that it has appointed Jane Spencer-Fry as vice president of sales, Europe.
Spencer-Fry most recently worked for BioVeris Europe as sales director. Prior to this, she held various commercial and scientific positions with Packard Biosciences (now PerkinElmer Life and Analytical Sciences) and Amersham Biosciences (now GE Healthcare).
Evotec has appointed David Brister chief business officer and a member of the executive committee, effective Oct. 16, the company said this week.
Brister will coordinate the business development activities of Evotec’s Pharmaceuticals and Services division, and will report to Joern Aldag, Evotec’s president and CEO.
Brister will join Evotec from MVM, a venture capital business focused on seed and early-stage healthcare investing. He has also served as an investment director at VC firm 3i. He holds a BSc in genetics and zoology from Sheffield University in the UK.
Kalypsys this week said that Richard Heyman has been appointed senior vice president of drug discovery, and Richard Lai Fatt has been appointed vice president of corporate development.
Heyman previously served as senior vice president of metabolic diseases for Exelixis. Prior to this, he was chief scientific officer and a co-founder of X-Ceptor Therapeutics.
Lai Fatt joins Kalypsys from Isis Pharmaceuticals, where he was vice president of business development and strategic marketing. He has also served as director of worldwide business development for DuPont Merck Pharmaceutical, and has held several sales and marketing positions with Schering-Plough and Lederle.